FiercePharmaOriginal article
{"a":[{"_":"Roche defends 6B franc Vabysmo peak sales target despite another quarterly miss","$":{"href":"/pharma/roche-defends-chf-6b-vabysmo-peak-sales-target-despite-another-quarterly-miss","hreflang":"en"}}]}
EarningsVabysmoNeutral
AI Analysis
Summary
Roche CEO Teresa Graham defended the company's 6 billion Swiss franc peak sales target for Vabysmo despite another quarterly sales miss, noting the U.S. branded market has stabilized but explosive growth from the drug's early launch period is likely behind it.
Financial Highlights
Guidance
Peak sales target of 6 billion Swiss francs for Vabysmo maintained
Outcome Details
Quarterly sales miss; CEO defended peak sales target of 6 billion Swiss francs
Importance:5/10
Sentiment:
-0.20
earningssales_missguidanceU.S. market
Related Companies
Read the original article
Published by FiercePharma on July 23, 2026 11:05 AM